vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and MEDIFAST INC (MED). Click either name above to swap in a different company.
MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $62.1M, roughly 1.2× Cytek Biosciences, Inc.). On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -36.9%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-6.6M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -34.4%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
CTKB vs MED — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $75.1M |
| Net Profit | $-44.1M | — |
| Gross Margin | 52.9% | 69.4% |
| Operating Margin | -9.0% | -10.4% |
| Net Margin | -70.9% | — |
| Revenue YoY | 8.1% | -36.9% |
| Net Profit YoY | -557.1% | — |
| EPS (diluted) | — | $-1.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $75.1M | ||
| Q3 25 | $52.3M | $89.4M | ||
| Q2 25 | $45.6M | $105.6M | ||
| Q1 25 | $41.5M | $115.7M | ||
| Q4 24 | $57.5M | $119.0M | ||
| Q3 24 | $51.5M | $140.2M | ||
| Q2 24 | $46.6M | $168.6M | ||
| Q1 24 | $44.9M | $174.7M |
| Q4 25 | $-44.1M | — | ||
| Q3 25 | $-5.5M | $-2.3M | ||
| Q2 25 | $-5.6M | $2.5M | ||
| Q1 25 | $-11.4M | $-772.0K | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $941.0K | $1.1M | ||
| Q2 24 | $-10.4M | $-8.2M | ||
| Q1 24 | $-6.2M | $8.3M |
| Q4 25 | 52.9% | 69.4% | ||
| Q3 25 | 52.7% | 69.5% | ||
| Q2 25 | 52.3% | 72.6% | ||
| Q1 25 | 48.6% | 72.8% | ||
| Q4 24 | 58.5% | 74.1% | ||
| Q3 24 | 56.3% | 75.4% | ||
| Q2 24 | 54.6% | 73.2% | ||
| Q1 24 | 51.3% | 72.8% |
| Q4 25 | -9.0% | -10.4% | ||
| Q3 25 | -17.6% | -4.6% | ||
| Q2 25 | -23.3% | -1.0% | ||
| Q1 25 | -36.1% | -1.1% | ||
| Q4 24 | 5.2% | 0.6% | ||
| Q3 24 | -8.2% | 1.5% | ||
| Q2 24 | -18.3% | -4.7% | ||
| Q1 24 | -23.9% | 4.5% |
| Q4 25 | -70.9% | — | ||
| Q3 25 | -10.5% | -2.5% | ||
| Q2 25 | -12.2% | 2.3% | ||
| Q1 25 | -27.5% | -0.7% | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 1.8% | 0.8% | ||
| Q2 24 | -22.4% | -4.8% | ||
| Q1 24 | -13.8% | 4.8% |
| Q4 25 | — | $-1.64 | ||
| Q3 25 | — | $-0.21 | ||
| Q2 25 | — | $0.22 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $-0.75 | ||
| Q1 24 | — | $0.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $167.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $198.9M |
| Total Assets | $461.5M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $167.3M | ||
| Q3 25 | $93.3M | $173.5M | ||
| Q2 25 | $75.5M | $162.7M | ||
| Q1 25 | $95.3M | $164.6M | ||
| Q4 24 | $98.7M | $162.3M | ||
| Q3 24 | $162.3M | $170.0M | ||
| Q2 24 | $177.9M | $163.5M | ||
| Q1 24 | $168.8M | $156.4M |
| Q4 25 | $341.7M | $198.9M | ||
| Q3 25 | $378.6M | $214.7M | ||
| Q2 25 | $377.6M | $216.0M | ||
| Q1 25 | $379.6M | $211.0M | ||
| Q4 24 | $395.7M | $210.1M | ||
| Q3 24 | $385.5M | $207.3M | ||
| Q2 24 | $389.1M | $205.3M | ||
| Q1 24 | $392.6M | $211.0M |
| Q4 25 | $461.5M | $248.0M | ||
| Q3 25 | $494.9M | $268.2M | ||
| Q2 25 | $493.3M | $269.3M | ||
| Q1 25 | $482.6M | $280.0M | ||
| Q4 24 | $499.5M | $284.2M | ||
| Q3 24 | $491.2M | $291.2M | ||
| Q2 24 | $483.7M | $293.5M | ||
| Q1 24 | $492.1M | $302.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-5.3M |
| Free Cash FlowOCF − Capex | $-1.8M | $-6.6M |
| FCF MarginFCF / Revenue | -2.9% | -8.8% |
| Capex IntensityCapex / Revenue | 1.6% | 1.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-5.3M | ||
| Q3 25 | $-3.9M | $12.1M | ||
| Q2 25 | $108.0K | $-3.4M | ||
| Q1 25 | $-125.0K | $3.4M | ||
| Q4 24 | $2.0M | $-4.9M | ||
| Q3 24 | $13.2M | $9.1M | ||
| Q2 24 | $6.2M | $13.1M | ||
| Q1 24 | $4.0M | $7.3M |
| Q4 25 | $-1.8M | $-6.6M | ||
| Q3 25 | $-4.6M | $10.8M | ||
| Q2 25 | $-1.5M | $-4.8M | ||
| Q1 25 | $-974.0K | $1.9M | ||
| Q4 24 | $1.1M | $-7.2M | ||
| Q3 24 | $12.2M | $7.7M | ||
| Q2 24 | $5.2M | $11.1M | ||
| Q1 24 | $3.4M | $5.4M |
| Q4 25 | -2.9% | -8.8% | ||
| Q3 25 | -8.7% | 12.0% | ||
| Q2 25 | -3.2% | -4.5% | ||
| Q1 25 | -2.3% | 1.6% | ||
| Q4 24 | 1.9% | -6.1% | ||
| Q3 24 | 23.7% | 5.5% | ||
| Q2 24 | 11.0% | 6.6% | ||
| Q1 24 | 7.6% | 3.1% |
| Q4 25 | 1.6% | 1.8% | ||
| Q3 25 | 1.3% | 1.5% | ||
| Q2 25 | 3.5% | 1.3% | ||
| Q1 25 | 2.0% | 1.3% | ||
| Q4 24 | 1.6% | 1.9% | ||
| Q3 24 | 2.0% | 1.0% | ||
| Q2 24 | 2.3% | 1.1% | ||
| Q1 24 | 1.3% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.36× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | 8.04× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
MED
Segment breakdown not available.
